相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Potential biomarkers of osteonecrosis in Gaucher disease
Elena V. Pavlova et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
The cytosolic β-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation
Nick Dekker et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant
Inna Bendikov-Bar et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
Ying Sun et al.
HUMAN MOLECULAR GENETICS (2010)
Ultrasensitive in situ visualization of active glucocerebrosidase molecules
Martin D. Witte et al.
NATURE CHEMICAL BIOLOGY (2010)
Velaglucerase alfa
Johannes M. F. G. Aerts et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sixteen years of prenatal consultations for the N370S/N370S Gaucher disease genotype: What have we learned?
Yale Eitan et al.
PRENATAL DIAGNOSIS (2010)
Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage
Pramod K. Mistry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Lysosomal disorders: From storage to cellular damage
Andrea Ballabio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2009)
Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates
Anton P. Bussink et al.
FEBS JOURNAL (2009)
Different dose-dependent correction of MIP-1β and chitotriosidase during initial enzyme replacement therapy
M. J. van Breemen et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2009)
Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease
Johannes M. Aerts et al.
ACTA PAEDIATRICA (2008)
Plasma lipids are altered in Gaucher disease: Biochemical markers to evaluate therapeutic intervention
Peter J. Meikle et al.
BLOOD CELLS MOLECULES AND DISEASES (2008)
Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease
Karen Ghauharall-van der Vlugt et al.
CLINICA CHIMICA ACTA (2008)
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III
J. Cox-Brinkman et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
Johannes M. Aerts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Non-neuronopathic Gaucher disease due to saposin C deficiency
Anna Tylki-Szymanska et al.
CLINICAL GENETICS (2007)
Monitoring of Gaucher patients with a novel chitotriosidase assay
Aricha Schoonhoven et al.
CLINICA CHIMICA ACTA (2007)
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels:: a 2-center retrospective analysis
Maaike de Fost et al.
BLOOD (2006)
Substrate reduction therapy of glycosphingolipid storage disorders
Johannes M. F. G. Aerts et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease
A Erikson et al.
ACTA PAEDIATRICA (2006)
Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity
M van Eijk et al.
INTERNATIONAL IMMUNOLOGY (2005)
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease
PB Deegan et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages
LA Boven et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
RG Boot et al.
BLOOD (2004)
Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms
E Lloyd-Evans et al.
BIOCHEMICAL JOURNAL (2003)
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement
TM Cox et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3
UH Schueler et al.
NEUROBIOLOGY OF DISEASE (2003)
Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter
M Maas et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2002)
Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype
E Orvisky et al.
MOLECULAR GENETICS AND METABOLISM (2002)
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy
FM Platt et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2001)
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
T Cox et al.
LANCET (2000)
分享论文
